Alzumab launches in India

[Fred]

Biocon, Asia's premier biotechnology company, today announced the launch of its ‘first in class’ novel biologic ALZUMAb™ (Itolizumab), the world’s first anti-CD6 monoclonal antibody to be introduced for treating patients with chronic plaque psoriasis, in India.

ALZUMAb™ (Itolizumab) is the world’s 'first-in-class' humanized anti-CD6 MAb that has a unique mechanism of action (MOA) targeting the CD6 pathway. CD6 is a pan T-Cell marker involved in co-stimulation, adhesion and maturation of T-Cells, which have been found to play a leading role in autoimmune diseases. ALZUMAb™ (Itolizumab), by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.

ALZUMAb™ with a unique Mechanism of Action (MOA) offers superior safety and similar efficacy profile compared to other existing therapies, and has a long remission period with very low opportunistic infection rate. Its launch in India for psoriasis is the first milestone on a promising and exciting journey towards new treatment options for life-changing autoimmune diseases. Biocon is committed to taking ALZUMAb™ (Itolizumab) from India to patients worldwide with a global partner.

Source: NO LINKS ALLOWED

[Caroline]

T-cells ?
Aren't those the things that are extremely important for your immunity against diseases?
What happens exactly when you down regulate their activation?

Maybe a good question for Krissie.

[Fred]

T-cells ?
Aren't those the things that are extremely important for your immunity against diseases?
What happens exactly when you down regulate their activation?

Maybe a good question for Krissie.

Yep those are the Guy's, a lot of the new treatments are trying to regulate the over production see this thread: T Cells the soldiers in your body

But yes Krissie would probably be able to explain it better.